Clinical value of peripheral venous blood circulating tumor cells count in patients with non -small cell lung cancer
10.3760/cma.j.issn.1008-6706.2016.12.003
- VernacularTitle:非小细胞肺癌患者外周静脉血循环肿瘤细胞计数的临床应用价值研究
- Author:
Chunshan LI
;
Yang YANG
;
Dan YAN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non -small cell lung;
Veins;
Cell count;
Tumor
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(12):1768-1771
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical value of peripheral venous blood circulating tumor cell count in patients with non -small -cell lung cancer (NSCLC).Methods 28 patients with NSCLC were chosen as observa-tion group,at the same time,16 patients with benign lung tumor and 16 healthy persons were chosen as the control group 1,2.Before and after treatment,the peripheral venous blood circulating tumor cell counts were studied to under-stand its value in clinical.Results CK -FITC expression rate of adenocarcinoma patients was 95.8%,CD326APC expression rate was 94.5%,CK -FITC and CD326APC expression rate was 94.6%.CK -FITC expression rate of squamous carcinoma was 93.7%,CD326APC expression rate was 93.9%,CK -FITC and CD326APC expression rate was 94.1%,the differences between the two groups were not significant (χ2 =2.89,1.36,2.14,all P >0.05).The positive rate of peripheral venous blood circulating tumor cells in the observation group was significantly higher than the two control groups,and before treatment,the positive rate of peripheral venous blood circulating tumor cell was higher than after treatment.Conclusion Peripheral venous blood circulating tumor cell count can determine the dis-ease development process.
